截至午间收盘，沪指报4095.54点，涨0.29%，深证成指涨0.35%，创业板指涨0.41%。 大家好，今天是周三，基金君和你继续关注市场行情！ 1月7日上午，A股三大股指集体上涨，沪指冲击4100点，再创10年来新高，市场量能强劲，半日成交额超1.8万亿元。 【导读】上午A股三大指数集体大涨，半导体、稀土板块大涨，光刻机概念股领涨 沪深两市半日成交额达1.84万亿元，较上个交易日放量538亿元。个股跌多涨少，全市场共2522只个股上涨，88只个股涨停，2773只个股下跌。 从板块看，半导体、基本金属、制药、煤炭等板块涨幅居前，光刻机、稀土概念股大涨；锂电电解液、金融科技等板块跌幅居前。 港股方面，在2026年开市大涨后，今天上午恒生指数、恒生科技指数、恒生中国企业指数等出现明显回调，跌幅均超1%。个股方面，腾讯控股跌超2%， 阿里巴巴跌超3%，小米集团、比亚迪（002594）、网易、美的纷纷下跌。恒生生物科技逆市上涨，康方生物、和黄医药涨超5%，翰森制药、亚盛医药、 科伦博泰生物、药明康德（603259）涨超3%。 | 序号 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | 成交额 | 年初至今 | ...

【导读】上午A股三大指数集体大涨，半导体、稀土板块大涨，光刻机概念股领涨 中国基金报记者 张舟 大家好，今天是周三，基金君和你继续关注市场行情！ 1月7日上午，A股三大股指集体上涨，沪指冲击4100点，再创10年来新高，市场量能强劲， 半日成交额超1.8万亿元。 截至午间收盘，沪指报4095.54点，涨0.29%，深证成指涨0.35%，创业板指涨0.41%。 | 最高： 4098.78 | 今开:4083.84 | 成交量: 4.32亿手 | 换手: 0. | | --- | --- | --- | --- | | 最低： 4075.70 | 昨收：4083.67 | 成交额：7617.22亿 | 量比: 1. | | 52周最高: 4098.78 | 上涨： 762 | 振幅: 0.57% | 平盘:74 | | 52周最低:3040.69 | 下跌:905 | 总市值: 66.86万亿 | | 沪深两市半日成交额达1.84万亿元，较上个交易日放量538亿元。 个股跌多涨少，全市场共 2522只个股上涨，88只个股涨停，2773只个股下跌。 上午，稀土永磁概念股强势拉升。 个股方面，中稀有色录得10cm涨停 ...

Core Insights - Elon Musk has provided a timeline for mass production of brain-computer interface (BCI) devices, igniting interest in global capital markets, with related indices in A-shares rising over 13% on the first trading day of the year [1] - Strong Brain Technology recently completed a significant financing round of approximately 2 billion RMB, marking the second-largest financing in the global BCI sector after Neuralink [1] - The Chinese government has included BCI technology in its "14th Five-Year Plan," indicating a strong push towards commercialization and innovation in the industry [1][3] Company Overview - Strong Brain Technology was founded in February 2015 and has developed non-invasive BCI technologies, including smart bionic limbs and sleep aids, achieving FDA and CE certifications [2] - The company has a history of substantial financing, including a $400 million Series A round in 2019, and plans for an IPO in Hong Kong or mainland China with a valuation exceeding $1.3 billion [2] Market Dynamics - The Chinese BCI market is projected to exceed 3.8 billion RMB by 2025, with medical health applications accounting for 56%, and is expected to surpass 10 billion RMB by 2030 [3] - The government plans to invest over 50 billion RMB in the BCI industry during the "14th Five-Year Plan," aiming to cultivate 2-3 global leading companies by 2030 [3] Future Development - Strong Brain Technology aims to accelerate research and development in rehabilitation and consumer sectors, with a vision to assist 1 million individuals with physical disabilities and 10 million patients suffering from brain-related conditions over the next 5 to 10 years [4] - The company emphasizes the importance of making BCI technology accessible to the general public, aligning with the "technology for good" philosophy [4] Global Industry Landscape - Neuralink remains the highest-valued BCI company globally, with a valuation of $9 billion following its Series E funding round in 2025 [5] - The BCI technology is expected to achieve commercialization by 2026, with applications expanding from medical needs to AI and robotics [5] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, indicating significant investment potential in both medical and technological sectors [5]

Core Viewpoint - The article highlights the significant financing of approximately 2 billion RMB by Strong Brain Technology, marking it as the second-largest disclosed financing in the global brain-computer interface (BCI) sector after Neuralink, drawing attention from both capital markets and the industry [2][3]. Financing Overview - Strong Brain Technology completed a financing round of about 2 billion RMB on January 6, 2026, with a diverse investor base including financial investors, industrial capital, and strategic investors such as IDG, Huaden International, and Lens Technology [2][14]. - This financing round reflects a continued interest in Strong Brain Technology's existing technology routes and product advancements, indicating confidence in the company's future [3][15]. - The company has a history of securing substantial capital, having previously completed multiple financing rounds, including a 20 million USD B round in 2025 and a 30 million USD Pre-B round [13][14]. Company and Product Development - Founded in February 2015, Strong Brain Technology has evolved into a key player in the BCI field, focusing on non-invasive BCI technology [7][9]. - The company has developed high-precision EEG signal acquisition and analysis technologies, achieving mass production of solid gel electrode materials in 2017, which improved the stability and accuracy of EEG signal collection [9]. - Strong Brain Technology has launched several BCI-related products, including smart bionic hands and legs, and a brain-machine intelligent sleep aid, with some products receiving FDA and CE certifications for international market entry [11][12]. Clinical and Market Progress - Strong Brain Technology's smart bionic hand is the first BCI product in China to receive FDA approval, allowing it to enter over 30 countries and regions by 2025 [12]. - The company holds over 200 core patents in the BCI field, with approximately 60% being invention patents, positioning it favorably in the domestic patent landscape [12]. Policy and Industry Support - The Chinese government has issued implementation opinions to promote innovation and development in the BCI industry, aiming for breakthroughs in key technologies by 2027 and establishing a robust industrial ecosystem by 2030 [16][17]. - Local governments, including Beijing and Shanghai, have introduced action plans to accelerate the application of BCI technologies across various sectors by 2030 [18][19]. Standardization and Ecosystem Development - The National Medical Products Administration released the first industry standard for BCI medical devices, effective January 1, 2026, to unify terminology and support regulatory and industrial collaboration [22]. - Various regions are also advancing infrastructure development to support BCI product research and application [23].

Market Overview - The A-share market opened high on January 7, with the Shanghai Composite Index rising by 0.29% to 4095.54 points, the Shenzhen Component Index up by 0.35% to 14071.35 points, and the ChiNext Index increasing by 0.41% to 3332.74 points, marking a four-year high [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.84 trillion yuan, an increase of 53.8 billion yuan compared to the previous trading day [1] Sector Performance - The photolithography concept stocks surged, with Guofeng New Materials hitting the limit up for two consecutive days, and several other stocks like Nanda Optoelectronics and Tongcheng New Materials also reaching the limit up [1] - The controllable nuclear fusion concept showed strong performance, with stocks like Wangzi New Materials and China First Heavy Industries hitting the limit up [1] - The brain-computer interface concept continued its strong trend, with stocks such as Innovation Medical and Nanjing Panda achieving three consecutive limit ups [1] - Semiconductor equipment stocks were actively traded, with stocks like Chip Source Microelectronics and Hengkun New Materials hitting the limit up by 20% [1] - The electric grid equipment sector showed strength, with Sanbian Technology and China West Electric reaching the limit up [1] - In contrast, oil and gas stocks performed poorly, with China National Offshore Oil Corporation experiencing a decline [1] Hot Sectors - The storage chip concept was strong, with stocks like Yingxin Development achieving two consecutive limit ups, and others like Puran Shares and Jiangbolong also rising [2] - The nickel concept stocks saw a rally, with stocks like Greeenmei hitting the limit up, supported by a significant increase in nickel prices [3] - The controllable nuclear fusion concept stocks rose, with breakthroughs in experimental methods reported, indicating long-term growth potential for the industry [4] Institutional Insights - Huaxi Securities noted that the spring market rally has started early, maintaining a bullish outlook, and suggested focusing on emerging growth sectors and anti-involution opportunities [5] - Shenwan Hongyuan Securities emphasized that the spring market structure remains unchanged, with high elasticity in thematic opportunities, particularly in AI and cyclical sectors [5] - Dongfang Securities indicated that the Shanghai Composite Index is approaching the 4100-point mark, predicting a slowdown in upward momentum and potential volatility [6]

Core Insights - The report from Guosen Securities indicates that brain-computer interfaces (BCIs) have reached a critical juncture for transitioning from technological breakthroughs to commercial viability, anchored by the "policy + technology + scenario" framework [1] - The industry is benefiting from policy incentives such as the 14th Five-Year Plan, medical insurance coding, and the establishment of medical device standards, alongside the anticipated mass production by Neuralink and breakthroughs in domestic clinical applications, suggesting a potential explosive growth in the global market [1] Product Development - In terms of product offerings, invasive products are still in clinical trials, while non-invasive products have seen some market entry, including medical brain-computer interface systems for motor rehabilitation and consumer sleep aids [1] - With advancements in chips, electrodes, and algorithms, along with the continuous improvement of regulatory standards, it is expected that brain-computer interface products will experience intensive commercialization in the coming years [1] Investment Recommendations - The report suggests focusing on core segments of the industry chain and technological pathways, prioritizing companies with competitive advantages [1] - For upstream investments, attention should be given to hardware suppliers of EEG sensors and core chips, which will benefit from the demand surge due to equipment mass production [1] - Midstream investments should target companies with core patents and clinical resources, particularly those in the invasive sector that can benchmark against international standards and those in the non-invasive sector that can quickly implement solutions [1] - Downstream, it is advisable to track companies that form commercial closed loops in rehabilitation medicine and industrial control, while also considering synergistic opportunities in "AI + brain-computer" and "robotics + brain-computer" ecosystems [1]

Summary of Dongwei Semiconductor's Conference Call Company Overview - **Company**: Dongwei Semiconductor - **Industry**: Brain-Computer Interface (BCI) and Power Solutions Key Points on Brain-Computer Interface Technology - **Liquid Flexible Electrode Technology**: Dongwei's liquid flexible electrode technology utilizes hydraulic injection to stiffen probes, eliminating the need for tungsten needle assistance. This method has shown a reduction in trauma by approximately 70% in mouse experiments, with ongoing trials in macaques expected to further validate its effectiveness in humans [2][3][5]. - **Comparison with Competitors**: Compared to companies like Neuralink, Dongwei's technology significantly reduces neuronal damage and immune response, enhancing long-term reliability. The effectiveness of their electrodes has improved by over 70% in animal tests [2][5][6]. - **Strategic Partnerships**: Dongwei has formed strategic collaborations with top hospitals, including Huashan Hospital, to support clinical applications and research [2][10]. - **Investment in R&D**: The company plans to invest a total of 1.5 billion yuan in chip development over three years, with an annual investment of approximately 100 million yuan in electrodes, clinical applications, and algorithms [2][11]. Development Plans and Market Position - **Full Industry Chain Control**: Dongwei aims to be a comprehensive invasive BCI company, controlling all aspects from electrodes to chips, algorithms, and clinical processes. This positions them uniquely in the market, as few domestic startups possess such capabilities [10][12]. - **Clinical Trials and Commercialization**: The company anticipates rapid commercialization of its products, potentially faster than competitors like Neuralink, due to lower costs and supportive policies in China. They expect to achieve significant clinical applications within two to three years [12][21]. - **Challenges in Chip Development**: Key challenges in BCI chip development include integrating various technologies such as digital, analog, power, transmission, and RF. Dongwei has accumulated expertise in these areas and plans to acquire or invest in relevant teams to enhance their product offerings [9][10]. Financial and Market Insights - **Cost Structure**: The cost of neural electrodes is influenced by various factors, with the most significant expenses arising from clinical procedures and maintenance rather than the electrodes themselves. As production scales up, marginal costs are expected to decrease [7]. - **Market Demand**: There is a strong domestic demand for specialized BCI chips, and Dongwei aims to meet this need through independent research and development [9][11]. Future Outlook - **Technological Aspirations**: Dongwei envisions BCI technology not only addressing disabilities but also enhancing the quality of life for the aging population, positioning it as a universal technology for human welfare [21][22]. - **Power Solutions Expansion**: The company is also focusing on power solutions, particularly in AI server power supply and silicon carbide devices, which are expected to see significant growth in the coming years [15][16][17]. Additional Insights - **Competitive Landscape**: Dongwei acknowledges the competitive nature of the semiconductor and BCI markets, with ongoing efforts to enhance their market share against established international players [18][19]. - **Long-term Vision**: The company aims to become a leading provider of advanced power solutions, focusing on efficient energy conversion and addressing structural opportunities in various sectors, including AIDC and renewable energy [22].

Summary of Neuralink and Brain-Computer Interface Industry Insights Company and Industry Overview - **Company**: Neuralink - **Industry**: Brain-Computer Interface (BCI) Key Points and Arguments 1. **Neuralink's Technological Progress**: Neuralink has achieved 1,024-channel motor area decoding and completed 20 human implants, with surgery efficiency improved to 20 minutes per case, aiming to reduce infection risks and enable industrial-scale production to lower costs [1][2][4]. 2. **Diverse BCI Technology Paths**: BCI technology includes non-invasive, semi-invasive, and invasive methods. Non-invasive methods are suitable for simple applications, while semi-invasive methods, like those from Boryung, have completed clinical trials. Invasive methods, such as Neuralink's, are used for high-precision decoding of motor, language, and visual signals [1][5]. 3. **Domestic Material Gaps**: There is a technological gap between domestic and overseas companies in upstream materials like electrode sensors and signal chips. However, Chinese companies are narrowing this gap through independent research and international collaboration [1][6][7]. 4. **Embedded BCI Functionality**: Embedded BCIs capture neural signals through electrodes, which are then processed by backend devices. Domestic companies are making strides in all aspects of this technology, gradually closing the gap with international leaders [1][8][9]. 5. **Algorithm Performance Challenges**: The performance of brain signal decoding algorithms relies on data quality and quantity. Collaborating with hospitals to obtain clinical data is crucial for enhancing algorithm performance, but lightweight devices face challenges in data collection [1][9]. 6. **Accuracy of BCI Systems**: Invasive BCIs like Neuralink achieve a 99% accuracy rate, while non-invasive methods have lower accuracy rates (70%-80% for motor imagery). Domestic companies are making progress but still lag behind in data accumulation [3][10]. 7. **Commercialization Barriers**: The key barrier to BCI commercialization is obtaining medical device registration. Once achieved, products can be legally sold and potentially covered by insurance, significantly enhancing market acceptance [11][12]. 8. **Market Growth Projections**: The BCI market is expected to reach $10 billion to $40 billion by 2030, with rapid growth in non-invasive products initially, followed by invasive products. If human-computer interaction solutions become mainstream, the market potential could expand significantly [11][12]. 9. **Investment Opportunities**: The most valuable investment segments in the BCI supply chain are chips and batteries, which are costly and complex to produce. There are opportunities in the primary market, but the secondary market requires careful evaluation of companies' actual involvement in BCI [13]. 10. **Regulatory and Economic Considerations**: BCI products must undergo rigorous evaluations for clinical effectiveness, safety, and economic viability before being included in insurance coverage. The process involves assessing clinical value and cost-effectiveness [15][14]. 11. **Ethical Considerations**: Neuralink's technology raises ethical concerns, particularly regarding the stimulation functions that could influence human behavior. This necessitates careful consideration of the applications and implications of such technologies [17]. 12. **Future Milestones**: Key milestones for the BCI industry include policy developments, clinical trial completions, and significant advancements from companies like Neuralink and Boryung, which will attract market attention [18]. Additional Important Insights - **Risks in the Current Market**: While the market is filled with opportunities, investors should remain cautious to avoid overlooking potential risks due to excessive optimism [19].

Summary of Key Points from the Conference Call Industry Overview - The conference call focused on the **brain-computer interface (BCI)** technology, which is categorized into invasive, semi-invasive, and non-invasive types, each with its own advantages and disadvantages [1][3][4]. Core Insights and Arguments - **Non-invasive BCIs** are primarily used for typing communication (based on P300), device control (based on SSVEP), and rehabilitation training (based on motor imagery potentials). However, they face limitations due to skull interference, resulting in low amplitude brain waves and a need for improved decoding accuracy [1][11][13]. - **Invasive BCIs** have made progress in motor and language decoding, as well as visual and auditory reconstruction, but they carry risks such as bleeding, infection, and device reliability issues, leading to uncertainty in commercialization prospects [1][15]. - A research team is exploring a hybrid approach combining **EEG and EMG** to decode motor intentions by analyzing weak muscle signals, which has shown success in helping patients with arm injuries and strokes regain some limb function, with plans for commercial use by mid-2025 [1][16][17]. - The market potential for hand function rehabilitation in China is significant, with over **50 million** patients suffering from limb disabilities and an annual increase of **2 to 3 million** cases [1][18]. Additional Important Content - The **clinical application** of EEG differs from BCI research, requiring higher sampling rates (1,000 Hz to 20,000 Hz) for effective data quality in BCI applications compared to the lower rates used in clinical settings [2]. - The **hardware segment** of the BCI industry has high barriers to entry and substantial profit margins, making it a promising investment area, especially in the context of China's healthcare payment habits [24]. - **Neuralink**, a prominent player in the invasive BCI space, has raised questions about its valuation and the practical benefits of its technology compared to non-invasive alternatives [23][22]. - The **supply chain** for BCI products is influenced by the compatibility of cost control and healthcare payment systems, particularly for non-invasive rehabilitation and invasive surgeries [24]. - Future applications of BCI technology may extend to treating mental health disorders and cognitive enhancement, although these areas still face significant challenges in decoding complex brain functions [26]. This summary encapsulates the key points discussed in the conference call, highlighting the current state and future potential of brain-computer interface technology.

麦澜德 20260106 摘要 中国脑计划推动脑机接口基础研究突破，正加速产业化落地。迈安德依 托国家重点研发计划，聚焦帕金森和阿尔兹海默症等认知功能障碍，已 积累多模态生理信号采集和神经调控技术。 迈安德选择非侵入式脑机接口技术路线，虽信号精度低于侵入式，但安 全性高、适用人群广，更易于医疗场景应用。公司已开发出脑机接口手 功能系统，并在多家医院进行临床应用。 迈安德在认知功能障碍领域，通过多模态生理信号采集识别患者情感状 态，结合神经调控与认知训练，干预大脑病灶。该项目预计 2027 年结 题，并推广应用。 在精神与心身疾病方面，迈安德完善生物反馈装备，结合外周训练与中 枢刺激，提升治疗效果。公司将传统单模态脑电拓展为加近红外双模态 信号采集，实现更立体的大脑观测。 国家政策支持力度加大，如 2025 年出台的政策文件规范医疗服务价格 及耗材引进，为脑机接口行业扫清障碍。中国脑机接口领域未来发展前 景广阔，应用场景将拓展至消费和教育领域。 Q&A 请介绍一下迈安德在脑机接口领域的布局及其未来规划。 迈安德在脑机接口领域的布局主要集中在康复和盆底业务板块。我们致力于通 过脑机接口技术实现身心同治，解决许多疾 ...